|MULTIPLE SCLEROSIS TREATMENTS|
|Tecfidera||120mg, 240mg||del-rel caps||120mg twice daily for 7 days, then increase to 240mg twice daily|
|fingolimod||Gilenya||0.25mg, 0.5mg||hard gel caps||(>40kg): 0.5mg once daily; (≤40kg): 0.25mg once daily. First dose monitoring for bradycardia or re-initiation of therapy: see full labeling.|
|Aubagio||7mg, 14mg||tabs||7mg or 14mg once daily|
|alemtuzumab||Lemtrada||12mg/1.2mL||soln for IV infusion after dilution||Premedicate with high-dose corticosteroids (eg, methylprednisolone 1000mg or equivalent) immediately prior to infusion and for the first 3 days of each treatment course; may consider antihistamines and/or antipyretics. Administer antivirals for herpetic prophylaxis on 1st day of each treatment course and for ≥2mos following treatment or until CD4+ lymphocyte count ≥200cells/μL, whichever occurs later. Give by IV infusion over 4hrs. ≥17yrs: First course: 12mg daily for 5 consecutive days; Second course: 12mg daily for 3 consecutive days given 12mos after first course.|
|glatiramer acetate||Copaxone||20mg/mL, 40mg/mL||soln for SC inj||20mg SC once daily or 40mg SC three times weekly (at least 48hrs apart). The 20mg/mL and 40mg/mL injections are not interchangeable.|
|interferon β-1a||Avonex||30mcg||soln for IM inj||30mcg IM once weekly. May titrate dose to reduce severity of flu-like symptoms; give once weekly, IM: Week 1: 7.5mcg. Week 2: 15mcg. Week 3: 22.5mcg. Week 4: 30mcg.|
|Rebif||8.8mcg/0.2mL, 22mcg/0.5mL, 44mcg/0.5mL||soln for SC inj||4.4mcg 3 times per week for 2wks, titrate to 22mcg 3 times per week by Week 5 OR 8.8mcg 3 times per week for 2wks, titrate to 44mcg 3 times per week by Week 5. Give by SC inj in PM at least 48hrs apart.|
|interferon β-1b||Betaseron||0.3mg||pwd for SC inj after reconstitution||0.0625mg (0.25mL) SC every other day; increase by 25% every 2wks to target dose of 0.25mg (1mL) every other day|
|—||2mg/mL||soln for IV infusion after dilution||12mg/m² IV over approx. 5–15mins every 3mos. Patients with LVEF <50%, significant reduction in LVEF, cumulative lifetime dose of ≥140mg/m2: not recommended.|
|natalizumab||Tysabri||300mg/15mL||soln for IV infusion after dilution||300mg IV over 1hr every 4wks|
|ocrelizumab||Ocrevus||30mg/mL||soln for IV infusion after dilution||Initially 300mg IV infusion, followed by a second 300mg infusion 2wks later, then 600mg infusion every 6mos thereafter. Premedicate with corticosteroid and antihistamine prior to each infusion; may consider antipyretic.|
|Plegridy||125mcg||soln for SC inj||Initially 63mcg on Day 1, increase to 94mcg on Day 15, then 125mcg on Day 29 and every 14 days thereafter. May give analgesics and/or antipyretics for flu‑like symptoms.|
Not an inclusive list of medications, dosing details and/or special considerations. Please see drug monograph at www.eMPR.com and/or contact company for full drug labeling.
Please login or register first to view this content.